Veloxis de Novo Kidney Transplant ECSWD

PHASE4UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 21, 2019

Primary Completion Date

July 31, 2021

Study Completion Date

June 30, 2022

Conditions
Kidney TransplantationImmunosuppression
Interventions
DRUG

Tacrolimus Extended Release Oral Tablet [Envarsus]

Tacrolimus Extended Release Oral Tablet \[Envarsus\]

DRUG

Mycophenolate Mofetil

Mycophenolate mofetil capsules or tablets

DRUG

Mycophenolic Acid Oral Product

mycophenolic acid tablets

DRUG

Tacrolimus

Twice daily tacrolimus

DRUG

Methylprednisolone

Methylprednisolone taper

DRUG

Prednisone

Prednisone taper

DRUG

Rabbit Anti-Human T-Lymphocyte Globulin Injectable Solution [Thymoglobulin]

Rabbit Anti-Human T-Lymphocyte Globulin

Trial Locations (2)

45219

RECRUITING

The Christ Hospital, Cincinnati

45267

RECRUITING

University of Cincinnati, Cincinnati

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Veloxis Pharmaceuticals

INDUSTRY

lead

Simon Tremblay, PharmD, PhD

OTHER